Results 11 to 20 of about 196,807 (276)

Mining natural products related to paclitaxel reveals the possible biosynthetic pathway of paclitaxel [PDF]

BIO Web of Conferences, 2023
Paclitaxel is a widely used anti-tumor drug. Currently, paclitaxel can only be extracted from plants or synthesized by chemical semi-synthesis, which cause environmental damage and cannot meet the growing demand.
Sun Juncong, Deng Juntao, Song Xinfang, Gu Miao, Yang Weiyang, Liu Min   +5 more
doaj   +1 more source

Perbandingan Respon Terapi dan Toksisitas Regimen Kemoterapi Kombinasi antara Paclitaxel, Carboplatin, dan Ifosfamide (TIP) dengan Paclitaxel dan Carboplatin (TP) pada Kanker Serviks Stadium IIb

Obgynia, 2023
Tujuan: Mengetahui perbandingan respon terapi dan toksisitas regimen kemoterapi kombinasi Paclitaxel Carboplatin Ifosfamide dengan Paclitaxel Carboplatin pada kanker serviks stadium IIB.
Nagusman Danil, Sharvianty Arifuddin, Eddy Hartono, Nur Rakhmah, Ajardiana, Syahrul Rauf, Andi Alfian Zainuddin   +6 more
doaj   +1 more source

Way to efficient microbial paclitaxel mass production

Synthetic and Systems Biotechnology, 2023
The microbial synthesis of paclitaxel is attractive for its short-cycle, cost-effectiveness, and sustainability. However, low paclitaxel productivity, depleted capacity during subculture and storage, and unclear biosynthesis mechanisms restrain ...
Chenyue Li, Yanli Qi, Zhongke Sun, Mengwan Jiang, Chengwei Li   +4 more
doaj   +1 more source

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas

Frontiers in Oncology, 2022
Taxanes (paclitaxel and docetaxel) play an important role in the treatment of advanced sarcomas. Albumin-bound paclitaxel (nab-paclitaxel) is a new kind of taxane and has many advantages compared with paclitaxel and docetaxel. Nab-paclitaxel is currently
Zhichao Tian, Weitao Yao
doaj   +1 more source

Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells

BMC Cancer, 2021
Background Paclitaxel (Taxol) is a microtubule-stabilizing drug used to treat several solid tumors, including ovarian, breast, non-small cell lung, and pancreatic cancers.
Celina Amaya, Shihua Luo, Julio Baigorri, Rogelio Baucells, Elizabeth R. Smith, Xiang-Xi Xu   +5 more
doaj   +1 more source

Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer

Frontiers in Oncology, 2022
ObjectiveWe conducted a phase 2 trial to compare the safety and efficacy of intravenous paclitaxel or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 in untreated advanced gastric cancer.MethodsParticipants with untreated advanced gastric cancer ...
Shen Zhao, Shen Zhao, Liyu Su, Yigui Chen, Xiaofeng Li, Peicheng Lin, Wujin Chen, Wenzheng Fang, Jinfeng Zhu, Hui Li, Liping Ren, Jie Liu, Yanni Hong, Shaowei Lin, Nanfeng Fan, Rongbo Lin, Rongbo Lin   +16 more
doaj   +1 more source

Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety

Biomedicines, 2023
Taxanes (paclitaxel and docetaxel) are one of the most useful classes of anticancer drugs. Taxanes are highly hydrophobic; therefore, these drugs must be dissolved in organic solvents (polysorbate or Cremophor EL), which contribute to their toxicities ...
Md Sazzad Hassan, Niranjan Awasthi, Saisantosh Ponna, Urs von Holzen   +3 more
doaj   +1 more source

Comparison of Peripheral Neuropathy Induced by Standard and Nanoparticle Albumin–Bound Paclitaxel in Rats

Journal of Pharmacological Sciences, 2011
.: Nanoparticle albumin–bound paclitaxel (nab-paclitaxel) is delivered to tumors and increases antitumor activity compared with solvent-based paclitaxel.
Yuji Yamashita, Nobuaki Egashira, Ken Masuguchi, Soichiro Ushio, Takehiro Kawashiri, Ryozo Oishi   +5 more
doaj   +1 more source

miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression. [PDF]

PLoS ONE, 2014
Non-small-cell lung cancer (NSCLC) is one of the most leading causes of cancer-related deaths worldwide. Paclitaxel based combination therapies have long been used as a standard treatment in aggressive NSCLCs.
Abhisek Chatterjee, Dhrubajyoti Chattopadhyay, Gopal Chakrabarti   +2 more
doaj   +1 more source

CPEB4-Promoted Paclitaxel Resistance in Ovarian Cancer In Vitro Relies on Translational Regulation of CSAG2

Frontiers in Pharmacology, 2021
Background: Drug resistance is a major obstacle in chemotherapy for ovarian cancer, wherein the up regulation of drug-resistant genes plays an important role.
Yaqing Zhang, Hongyun Gan, Fei Zhao, Xiaomei Ma, Xiaofeng Xie, Rui Huang, Jin Zhao   +6 more
doaj   +1 more source